A cost analysis of producing vaccines in developing countries

Syarifah Liza Munira, Jan T. Hendriks, Ines I. Atmosukarto, Martin H. Friede, Louise M. Carter, James R.G. Butler, Archie C.A. Clements

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Developing country vaccine manufacturers (DCVMs) supply over half of the vaccines used in developing country immunisation programs. Decisions by developing countries to establish vaccine manufacturing should be based on economic viability, however reliable assessments of vaccine production costs are lacking. This study aimed to quantify the cost of establishing vaccine manufacturing facilities and producing vaccines in developing countries. This study estimates vaccine production costs in developing countries based on twelve vaccines produced by eight DCVMs. The results were based on estimates of the capital and operating costs required to establish vaccine manufacturing facilities under three hypothetical scenarios of production scale and scope. Cost patterns were then compared to vaccine prices paid by countries in both industrialized and developing country markets. The cost of producing vaccines in developing countries was estimated to be on average US$ 2.18 per dose, ranging between US$ 0.98 and US$ 4.85 for different vaccine types and formulations. Vaccine costs-per-dose decrease as production scale and scope increase. Cost-per-dose is mainly driven by fixed costs, but at a scale of production over 20 million doses per year it becomes driven by variable costs. Under the three hypothetical scenarios used, costs-per-dose of vaccines produced by developing countries were around 47% lower than vaccine prices in developing-country markets and 84% lower than prices in industrialized-country markets. This study has found that local production of vaccines in developing countries exhibits both economies of scale and economies of scope. The lower costs relative to prices suggests that a producer surplus and potential profits may be attainable in both developing and developed country markets, supporting sustainable production.

Original languageEnglish
Pages (from-to)1245-1251
Number of pages7
JournalVaccine
Volume37
Issue number9
DOIs
Publication statusPublished - 21 Feb 2019

Fingerprint

cost analysis
Developing Countries
developing countries
Vaccines
vaccines
Costs and Cost Analysis
Developed Countries
developed countries
markets
dosage
manufacturing
production costs
Economics
economic sustainability
economies of scale
variable costs
Immunization Programs
operating costs

Keywords

  • Cost analysis
  • Developing country
  • Vaccine
  • Vaccine production

Cite this

Munira, S. L., Hendriks, J. T., Atmosukarto, I. I., Friede, M. H., Carter, L. M., Butler, J. R. G., & Clements, A. C. A. (2019). A cost analysis of producing vaccines in developing countries. Vaccine, 37(9), 1245-1251. https://doi.org/10.1016/j.vaccine.2018.11.050
Munira, Syarifah Liza ; Hendriks, Jan T. ; Atmosukarto, Ines I. ; Friede, Martin H. ; Carter, Louise M. ; Butler, James R.G. ; Clements, Archie C.A. / A cost analysis of producing vaccines in developing countries. In: Vaccine. 2019 ; Vol. 37, No. 9. pp. 1245-1251.
@article{ca17330a422d48f2a444cdf26d7436f0,
title = "A cost analysis of producing vaccines in developing countries",
abstract = "Developing country vaccine manufacturers (DCVMs) supply over half of the vaccines used in developing country immunisation programs. Decisions by developing countries to establish vaccine manufacturing should be based on economic viability, however reliable assessments of vaccine production costs are lacking. This study aimed to quantify the cost of establishing vaccine manufacturing facilities and producing vaccines in developing countries. This study estimates vaccine production costs in developing countries based on twelve vaccines produced by eight DCVMs. The results were based on estimates of the capital and operating costs required to establish vaccine manufacturing facilities under three hypothetical scenarios of production scale and scope. Cost patterns were then compared to vaccine prices paid by countries in both industrialized and developing country markets. The cost of producing vaccines in developing countries was estimated to be on average US$ 2.18 per dose, ranging between US$ 0.98 and US$ 4.85 for different vaccine types and formulations. Vaccine costs-per-dose decrease as production scale and scope increase. Cost-per-dose is mainly driven by fixed costs, but at a scale of production over 20 million doses per year it becomes driven by variable costs. Under the three hypothetical scenarios used, costs-per-dose of vaccines produced by developing countries were around 47{\%} lower than vaccine prices in developing-country markets and 84{\%} lower than prices in industrialized-country markets. This study has found that local production of vaccines in developing countries exhibits both economies of scale and economies of scope. The lower costs relative to prices suggests that a producer surplus and potential profits may be attainable in both developing and developed country markets, supporting sustainable production.",
keywords = "Cost analysis, Developing country, Vaccine, Vaccine production",
author = "Munira, {Syarifah Liza} and Hendriks, {Jan T.} and Atmosukarto, {Ines I.} and Friede, {Martin H.} and Carter, {Louise M.} and Butler, {James R.G.} and Clements, {Archie C.A.}",
year = "2019",
month = "2",
day = "21",
doi = "10.1016/j.vaccine.2018.11.050",
language = "English",
volume = "37",
pages = "1245--1251",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "9",

}

Munira, SL, Hendriks, JT, Atmosukarto, II, Friede, MH, Carter, LM, Butler, JRG & Clements, ACA 2019, 'A cost analysis of producing vaccines in developing countries', Vaccine, vol. 37, no. 9, pp. 1245-1251. https://doi.org/10.1016/j.vaccine.2018.11.050

A cost analysis of producing vaccines in developing countries. / Munira, Syarifah Liza; Hendriks, Jan T.; Atmosukarto, Ines I.; Friede, Martin H.; Carter, Louise M.; Butler, James R.G.; Clements, Archie C.A.

In: Vaccine, Vol. 37, No. 9, 21.02.2019, p. 1245-1251.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A cost analysis of producing vaccines in developing countries

AU - Munira, Syarifah Liza

AU - Hendriks, Jan T.

AU - Atmosukarto, Ines I.

AU - Friede, Martin H.

AU - Carter, Louise M.

AU - Butler, James R.G.

AU - Clements, Archie C.A.

PY - 2019/2/21

Y1 - 2019/2/21

N2 - Developing country vaccine manufacturers (DCVMs) supply over half of the vaccines used in developing country immunisation programs. Decisions by developing countries to establish vaccine manufacturing should be based on economic viability, however reliable assessments of vaccine production costs are lacking. This study aimed to quantify the cost of establishing vaccine manufacturing facilities and producing vaccines in developing countries. This study estimates vaccine production costs in developing countries based on twelve vaccines produced by eight DCVMs. The results were based on estimates of the capital and operating costs required to establish vaccine manufacturing facilities under three hypothetical scenarios of production scale and scope. Cost patterns were then compared to vaccine prices paid by countries in both industrialized and developing country markets. The cost of producing vaccines in developing countries was estimated to be on average US$ 2.18 per dose, ranging between US$ 0.98 and US$ 4.85 for different vaccine types and formulations. Vaccine costs-per-dose decrease as production scale and scope increase. Cost-per-dose is mainly driven by fixed costs, but at a scale of production over 20 million doses per year it becomes driven by variable costs. Under the three hypothetical scenarios used, costs-per-dose of vaccines produced by developing countries were around 47% lower than vaccine prices in developing-country markets and 84% lower than prices in industrialized-country markets. This study has found that local production of vaccines in developing countries exhibits both economies of scale and economies of scope. The lower costs relative to prices suggests that a producer surplus and potential profits may be attainable in both developing and developed country markets, supporting sustainable production.

AB - Developing country vaccine manufacturers (DCVMs) supply over half of the vaccines used in developing country immunisation programs. Decisions by developing countries to establish vaccine manufacturing should be based on economic viability, however reliable assessments of vaccine production costs are lacking. This study aimed to quantify the cost of establishing vaccine manufacturing facilities and producing vaccines in developing countries. This study estimates vaccine production costs in developing countries based on twelve vaccines produced by eight DCVMs. The results were based on estimates of the capital and operating costs required to establish vaccine manufacturing facilities under three hypothetical scenarios of production scale and scope. Cost patterns were then compared to vaccine prices paid by countries in both industrialized and developing country markets. The cost of producing vaccines in developing countries was estimated to be on average US$ 2.18 per dose, ranging between US$ 0.98 and US$ 4.85 for different vaccine types and formulations. Vaccine costs-per-dose decrease as production scale and scope increase. Cost-per-dose is mainly driven by fixed costs, but at a scale of production over 20 million doses per year it becomes driven by variable costs. Under the three hypothetical scenarios used, costs-per-dose of vaccines produced by developing countries were around 47% lower than vaccine prices in developing-country markets and 84% lower than prices in industrialized-country markets. This study has found that local production of vaccines in developing countries exhibits both economies of scale and economies of scope. The lower costs relative to prices suggests that a producer surplus and potential profits may be attainable in both developing and developed country markets, supporting sustainable production.

KW - Cost analysis

KW - Developing country

KW - Vaccine

KW - Vaccine production

UR - http://www.scopus.com/inward/record.url?scp=85059800387&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2018.11.050

DO - 10.1016/j.vaccine.2018.11.050

M3 - Article

VL - 37

SP - 1245

EP - 1251

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 9

ER -

Munira SL, Hendriks JT, Atmosukarto II, Friede MH, Carter LM, Butler JRG et al. A cost analysis of producing vaccines in developing countries. Vaccine. 2019 Feb 21;37(9):1245-1251. https://doi.org/10.1016/j.vaccine.2018.11.050